{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:25:32Z","timestamp":1793715932540,"version":"4.6.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00125-026-06726-1","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:52:21Z","timestamp":1779385941000},"page":"3034-3047","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["MASLD prevalence, incidence and global aspects"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7824-2569","authenticated-orcid":false,"given":"Sarah H.","family":"Wild","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-2299","authenticated-orcid":false,"given":"Jeffrey V.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3199-301X","authenticated-orcid":false,"given":"C. Wendy","family":"Spearman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6120-1055","authenticated-orcid":false,"given":"Ponsiano","family":"Ocama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4665-3886","authenticated-orcid":false,"given":"Josh","family":"Bilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8534-0818","authenticated-orcid":false,"given":"Xiao-Dong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-2631","authenticated-orcid":false,"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6322-7753","authenticated-orcid":false,"given":"Christopher D.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"6726_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003","journal-title":"J Hepatol"},{"key":"6726_CR2","doi-asserted-by":"publisher","first-page":"1411802","DOI":"10.3389\/fnut.2024.1411802","volume":"11","author":"H Zou","year":"2024","unstructured":"Zou H, Ma X, Pan W, Xie Y (2024) Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population. Front Nutr 11:1411802. https:\/\/doi.org\/10.3389\/fnut.2024.1411802","journal-title":"Front Nutr"},{"key":"6726_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325724","author":"TG Simon","year":"2021","unstructured":"Simon TG, Roelstraete B, Hagstr\u00f6m H, Sundstr\u00f6m J, Ludvigsson JF (2021) Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut. https:\/\/doi.org\/10.1136\/gutjnl-2021-325724","journal-title":"Gut"},{"issue":"3","key":"6726_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/s2213-8587(19)30026-9","volume":"7","author":"LM Jaacks","year":"2019","unstructured":"Jaacks LM, Vandevijvere S, Pan A et al (2019) The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol 7(3):231\u2013240. https:\/\/doi.org\/10.1016\/s2213-8587(19)30026-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"6726_CR5","doi-asserted-by":"publisher","first-page":"e13601","DOI":"10.1111\/obr.13601","volume":"24","author":"B Daran","year":"2023","unstructured":"Daran B, Levasseur P, Cl\u00e9ment M (2023) Updating the association between socioeconomic status and obesity in low-income and lower-middle-income sub-Saharan African countries: a literature review. Obes Rev 24(10):e13601. https:\/\/doi.org\/10.1111\/obr.13601","journal-title":"Obes Rev"},{"issue":"1S","key":"6726_CR6","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G (2015) NAFLD: a multisystem disease. J Hepatol 62(1S):S47\u2013S64. https:\/\/doi.org\/10.1016\/j.jhep.2014.12.012","journal-title":"J Hepatol"},{"issue":"4","key":"6726_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H (2024) MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 73(4):691\u2013702. https:\/\/doi.org\/10.1136\/gutjnl-2023-330595","journal-title":"Gut"},{"issue":"7","key":"6726_CR8","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","volume":"393","author":"G Targher","year":"2025","unstructured":"Targher G, Valenti L, Byrne CD (2025) Metabolic dysfunction-associated steatotic liver disease. N Engl J Med 393(7):683\u2013698. https:\/\/doi.org\/10.1056\/NEJMra2412865","journal-title":"N Engl J Med"},{"key":"6726_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.01.013","author":"CD Byrne","year":"2020","unstructured":"Byrne CD, Targher G (2020) NAFLD as a driver of chronic kidney disease. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2020.01.013","journal-title":"J Hepatol"},{"key":"6726_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.12.026","author":"A Krag","year":"2026","unstructured":"Krag A, Tacke F, Israelsen M, Younossi ZM (2026) Is liver steatosis a disease or the emperor\u2019s new clothes? J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2025.12.026","journal-title":"J Hepatol"},{"key":"6726_CR11","unstructured":"United Nations (2024) Global issues: population. Available from: https:\/\/www.un.org\/en\/global-issues\/population. Accessed: 12 Dec 2025"},{"issue":"2","key":"6726_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s2213-8587(25)00299-2","volume":"14","author":"I Genitsaridi","year":"2026","unstructured":"Genitsaridi I, Salpea P, Salim A et al (2026) 11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050. Lancet Diabetes Endocrinol 14(2):149\u2013156. https:\/\/doi.org\/10.1016\/s2213-8587(25)00299-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10397","key":"6726_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/s0140-6736(23)01301-6","volume":"402","author":"GBD 2021 Diabetes Collaborators","year":"2023","unstructured":"GBD 2021 Diabetes Collaborators (2023) Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402(10397):203\u2013234. https:\/\/doi.org\/10.1016\/s0140-6736(23)01301-6","journal-title":"Lancet"},{"issue":"3","key":"6726_CR14","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","volume":"79","author":"VW-S Wong","year":"2023","unstructured":"Wong VW-S, Ekstedt M, Wong GL-H, Hagstr\u00f6m H (2023) Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol 79(3):842\u2013852. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.036","journal-title":"J Hepatol"},{"issue":"1","key":"6726_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","volume":"11","author":"DQ Huang","year":"2025","unstructured":"Huang DQ, Wong VWS, Rinella ME et al (2025) Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers 11(1):14. https:\/\/doi.org\/10.1038\/s41572-025-00599-1","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"6726_CR16","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","volume":"169","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Zelber-Sagi S, Lazarus JV et al (2025) Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis. Gastroenterology 169(5):1017-1032.e1012. https:\/\/doi.org\/10.1053\/j.gastro.2025.02.044","journal-title":"Gastroenterology"},{"issue":"9","key":"6726_CR17","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/s2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH et al (2022) The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 7(9):851\u2013861. https:\/\/doi.org\/10.1016\/s2468-1253(22)00165-0","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"6726_CR18","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","volume":"72","author":"E En Li Cho","year":"2023","unstructured":"En Li Cho E, Ang CZ, Quek J et al (2023) Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut 72(11):2138\u20132148. https:\/\/doi.org\/10.1136\/gutjnl-2023-330110","journal-title":"Gut"},{"issue":"3","key":"6726_CR19","doi-asserted-by":"publisher","first-page":"101271","DOI":"10.1016\/j.jhepr.2024.101271","volume":"7","author":"G Feng","year":"2025","unstructured":"Feng G, Targher G, Byrne CD et al (2025) Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021. JHEP Rep Innov Hepatol 7(3):101271. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101271","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"6","key":"6726_CR20","doi-asserted-by":"publisher","first-page":"e2516367","DOI":"10.1001\/jamanetworkopen.2025.16367","volume":"8","author":"X Zhang","year":"2025","unstructured":"Zhang X, Linden S, Levesley CR et al (2025) Projected trends in metabolic dysfunction-associated steatotic liver disease mortality through 2040. JAMA Netw Open 8(6):e2516367\u2013e2516367. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.16367","journal-title":"JAMA Netw Open"},{"issue":"3","key":"6726_CR21","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jhep.2025.03.001","volume":"83","author":"G Issa","year":"2025","unstructured":"Issa G, Shang Y, Strandberg R, Hagstr\u00f6m H, Wester A (2025) Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden. J Hepatol 83(3):643\u2013651. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.001","journal-title":"J Hepatol"},{"issue":"1","key":"6726_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431","journal-title":"Hepatology"},{"issue":"11","key":"6726_CR23","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S2468-1253(22)00041-3","volume":"7","author":"CW Spearman","year":"2022","unstructured":"Spearman CW, Dusheiko G, Jonas E et al (2022) Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa. Lancet Gastroenterol Hepatol 7(11):1036\u20131048. https:\/\/doi.org\/10.1016\/S2468-1253(22)00041-3","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6726_CR24","unstructured":"Roser MR, H; Rosado P (2013) Food supply. Available from: https:\/\/ourworldindata.org\/food-supply. Accessed: 12 Dec 2025"},{"issue":"10481","key":"6726_CR25","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/s0140-6736(25)00355-1","volume":"405","author":"GBD 2021 Adult BMI Collaborators","year":"2025","unstructured":"GBD 2021 Adult BMI Collaborators (2025) Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet 405(10481):813\u2013838. https:\/\/doi.org\/10.1016\/s0140-6736(25)00355-1","journal-title":"Lancet"},{"issue":"1","key":"6726_CR26","doi-asserted-by":"publisher","first-page":"5178","DOI":"10.1038\/s41598-021-84344-0","volume":"11","author":"SJ Nkambule","year":"2021","unstructured":"Nkambule SJ, Moodley I, Kuupiel D, Mashamba-Thompson TP (2021) Association between food insecurity and key metabolic risk factors for diet-sensitive non-communicable diseases in sub-Saharan Africa: a systematic review and meta-analysis. Sci Rep 11(1):5178. https:\/\/doi.org\/10.1038\/s41598-021-84344-0","journal-title":"Sci Rep"},{"key":"6726_CR27","doi-asserted-by":"publisher","unstructured":"Hasanoglu I, Rivero-Ju\u00e1rez A, \u00d6zkaya \u015eahin G, Escmid Study Group For Viral Hepatitis Esgvh (2025) When metabolic dysfunction-associated steatotic liver disease meets viral hepatitis. J Clin Med 14(10). https:\/\/doi.org\/10.3390\/jcm14103422","DOI":"10.3390\/jcm14103422"},{"key":"6726_CR28","volume-title":"Global hepatitis report 2024: action for access in low- and middle-income countries","author":"WHO","year":"2024","unstructured":"WHO (2024) Global hepatitis report 2024: action for access in low- and middle-income countries. WHO, Geneva"},{"key":"6726_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001058","author":"D IvancovskyWajcman","year":"2024","unstructured":"IvancovskyWajcman D, Byrne CJ, Dillon JF et al (2024) A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease. Hepatology. https:\/\/doi.org\/10.1097\/hep.0000000000001058","journal-title":"Hepatology"},{"issue":"12","key":"6726_CR30","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41575-024-00967-4","volume":"21","author":"LY Mak","year":"2024","unstructured":"Mak LY, Liu K, Chirapongsathorn S et al (2024) Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions. Nat Rev Gastroenterol Hepatol 21(12):834\u2013851. https:\/\/doi.org\/10.1038\/s41575-024-00967-4","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"6726_CR31","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/hep.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77(4):1335\u20131347. https:\/\/doi.org\/10.1097\/hep.0000000000000004","journal-title":"Hepatology"},{"key":"6726_CR32","doi-asserted-by":"publisher","first-page":"155999","DOI":"10.1016\/j.metabol.2024.155999","volume":"160","author":"H Zhang","year":"2024","unstructured":"Zhang H, Zhou XD, Shapiro MD et al (2024) Global burden of metabolic diseases, 1990\u20132021. Metabolism 160:155999. https:\/\/doi.org\/10.1016\/j.metabol.2024.155999","journal-title":"Metabolism"},{"issue":"12","key":"6726_CR33","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.14309\/ajg.0000000000003421","volume":"120","author":"M Abu-Rumaileh","year":"2025","unstructured":"Abu-Rumaileh M, Dhoop S, Pace J et al (2025) Social determinants of health associated with metabolic dysfunction-associated steatotic liver disease prevalence and severity: a systematic review and meta-analysis. Am J Gastroenterol 120(12):2810\u20132820. https:\/\/doi.org\/10.14309\/ajg.0000000000003421","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"6726_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1010539513481494","volume":"25","author":"AM M\u00fcller","year":"2013","unstructured":"M\u00fcller AM, Khoo S, Lambert R (2013) Review of physical activity prevalence of Asian school-age children and adolescents. Asia Pac J Public Health 25(3):227\u2013238. https:\/\/doi.org\/10.1177\/1010539513481494","journal-title":"Asia Pac J Public Health"},{"issue":"4","key":"6726_CR35","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jshs.2017.09.013","volume":"6","author":"BE Ainsworth","year":"2017","unstructured":"Ainsworth BE (2017) Step it up: promoting physical activity in school-aged children and adolescents in China. J Sport Health Sci 6(4):386\u2013387. https:\/\/doi.org\/10.1016\/j.jshs.2017.09.013","journal-title":"J Sport Health Sci"},{"key":"6726_CR36","doi-asserted-by":"publisher","first-page":"1499735","DOI":"10.3389\/fendo.2024.1499735","volume":"15","author":"R Wang","year":"2024","unstructured":"Wang R, Wu N, Qu H et al (2024) The association between working hours and working type with non-alcoholic fatty liver disease: results from the NHANES 1999\u20132014. Front Endocrinol 15:1499735. https:\/\/doi.org\/10.3389\/fendo.2024.1499735","journal-title":"Front Endocrinol"},{"issue":"10005","key":"6726_CR37","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/s0140-6736(15)60295-1","volume":"386","author":"M Kivim\u00e4ki","year":"2015","unstructured":"Kivim\u00e4ki M, Jokela M, Nyberg ST et al (2015) Long working hours and risk of coronary heart disease and stroke: a systematic review and meta-analysis of published and unpublished data for 603,838 individuals. Lancet 386(10005):1739\u20131746. https:\/\/doi.org\/10.1016\/s0140-6736(15)60295-1","journal-title":"Lancet"},{"issue":"1","key":"6726_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s2213-8587(14)70178-0","volume":"3","author":"M Kivim\u00e4ki","year":"2015","unstructured":"Kivim\u00e4ki M, Virtanen M, Kawachi I et al (2015) Long working hours, socioeconomic status, and the risk of incident type 2 diabetes: a meta-analysis of published and unpublished data from 222 120 individuals. Lancet Diabetes Endocrinol 3(1):27\u201334. https:\/\/doi.org\/10.1016\/s2213-8587(14)70178-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"6726_CR39","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1111\/jgh.15496","volume":"36","author":"CK Tan","year":"2021","unstructured":"Tan CK, Goh GB, Youn J, Yu JC, Singh S (2021) Public awareness and knowledge of liver health and diseases in Singapore. J Gastroenterol Hepatol 36(8):2292\u20132302. https:\/\/doi.org\/10.1111\/jgh.15496","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"6726_CR40","doi-asserted-by":"publisher","first-page":"e14799","DOI":"10.1111\/dme.14799","volume":"39","author":"L Gracen","year":"2022","unstructured":"Gracen L, Hayward KL, Aikebuse M et al (2022) An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care. Diabet Med 39(6):e14799. https:\/\/doi.org\/10.1111\/dme.14799","journal-title":"Diabet Med"},{"issue":"3","key":"6726_CR41","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jhep.2023.11.004","volume":"80","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Alqahtani SA, Alswat K et al (2024) Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. J Hepatol 80(3):419\u2013430. https:\/\/doi.org\/10.1016\/j.jhep.2023.11.004","journal-title":"J Hepatol"},{"issue":"1","key":"6726_CR42","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s43856-024-00649-x","volume":"4","author":"LA D\u00edaz","year":"2024","unstructured":"D\u00edaz LA, Lazarus JV, Fuentes-L\u00f3pez E et al (2024) Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria. Commun Med (Lond) 4(1):219. https:\/\/doi.org\/10.1038\/s43856-024-00649-x","journal-title":"Commun Med (Lond)"},{"issue":"12","key":"6726_CR43","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/s2468-1253(25)00226-2","volume":"10","author":"P Iruzubieta","year":"2025","unstructured":"Iruzubieta P, de Vega T, Crespo J (2025) Overlooked determinants and unequal outcomes: rethinking metabolic dysfunction-associated steatotic liver disease beyond the biomedical model. Lancet Gastroenterol Hepatol 10(12):1132\u20131142. https:\/\/doi.org\/10.1016\/s2468-1253(25)00226-2","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"21","key":"6726_CR44","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.3390\/jcm10215019","volume":"10","author":"M Talens","year":"2021","unstructured":"Talens M, Tumas N, Lazarus JV, Benach J, Peric\u00e0s JM (2021) What do we know about inequalities in NAFLD distribution and outcomes? A scoping review. J Clin Med 10(21):5019. https:\/\/doi.org\/10.3390\/jcm10215019","journal-title":"J Clin Med"},{"issue":"11","key":"6726_CR45","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/jamainternmed.2025.4769","volume":"185","author":"NA Cumpian","year":"2025","unstructured":"Cumpian NA, Gutierrez JA, Wu W, Saab S (2025) Targeting MASLD and MASH in the US Hispanic\/Latino population: a review. JAMA Int Med 185(11):1376\u20131386. https:\/\/doi.org\/10.1001\/jamainternmed.2025.4769","journal-title":"JAMA Int Med"},{"issue":"3","key":"6726_CR46","doi-asserted-by":"publisher","first-page":"e252208","DOI":"10.1001\/jamanetworkopen.2025.2208","volume":"8","author":"PS Pinheiro","year":"2025","unstructured":"Pinheiro PS, Zhang J, Setiawan VW, Cranford HM, Wong RJ, Liu L (2025) Liver cancer etiology in Asian subgroups and American Indian, Black, Latino, and White populations. JAMA Netw Open 8(3):e252208. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.2208","journal-title":"JAMA Netw Open"},{"issue":"10","key":"6726_CR47","doi-asserted-by":"publisher","first-page":"e70311","DOI":"10.1111\/liv.70311","volume":"45","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Wong VW, Tsochatzis EA et al (2025) Managing MASLD through preventive hepatology: integrating policy reform, public health and personalised care. Liver Int 45(10):e70311. https:\/\/doi.org\/10.1111\/liv.70311","journal-title":"Liver Int"},{"issue":"2","key":"6726_CR48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/s2468-1253(19)30342-5","volume":"5","author":"SK Sarin","year":"2020","unstructured":"Sarin SK, Kumar M, Eslam M et al (2020) Liver diseases in the Asia-Pacific region: a lancet gastroenterology & hepatology commission. Lancet Gastroenterol Hepatol 5(2):167\u2013228. https:\/\/doi.org\/10.1016\/s2468-1253(19)30342-5","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6726_CR49","doi-asserted-by":"publisher","first-page":"101717","DOI":"10.1016\/j.lanwpc.2025.101717","volume":"64","author":"X Li","year":"2025","unstructured":"Li X, Zhou XD, Wu J et al (2025) Pediatric MASLD in China: epidemiology, screening, diagnosis, and management. Lancet Reg Health West Pac 64:101717. https:\/\/doi.org\/10.1016\/j.lanwpc.2025.101717","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"6726_CR50","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1057\/s41271-018-00158-x","volume":"40","author":"S Greenhalgh","year":"2019","unstructured":"Greenhalgh S (2019) Soda industry influence on obesity science and policy in China. J Public Health Policy 40(1):5\u201316. https:\/\/doi.org\/10.1057\/s41271-018-00158-x","journal-title":"J Public Health Policy"},{"issue":"4","key":"6726_CR51","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s13668-021-00381-1","volume":"10","author":"AJ Cameron","year":"2021","unstructured":"Cameron AJ, Reeve E, Marshall J et al (2021) A proposed research agenda for promoting healthy retail food environments in the east Asia-pacific region. Curr Nutr Rep 10(4):267\u2013281. https:\/\/doi.org\/10.1007\/s13668-021-00381-1","journal-title":"Curr Nutr Rep"},{"key":"6726_CR52","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.envint.2019.02.004","volume":"126","author":"L Aleksandrowicz","year":"2019","unstructured":"Aleksandrowicz L, Green R, Joy EJM et al (2019) Environmental impacts of dietary shifts in India: A modelling study using nationally-representative data. Environ Int 126:207\u2013215. https:\/\/doi.org\/10.1016\/j.envint.2019.02.004","journal-title":"Environ Int"},{"issue":"11","key":"6726_CR53","doi-asserted-by":"publisher","first-page":"e797","DOI":"10.1016\/s2542-5196(21)00251-5","volume":"5","author":"M Springmann","year":"2021","unstructured":"Springmann M, Clark MA, Rayner M, Scarborough P, Webb P (2021) The global and regional costs of healthy and sustainable dietary patterns: a modelling study. Lancet Planet Health 5(11):e797\u2013e807. https:\/\/doi.org\/10.1016\/s2542-5196(21)00251-5","journal-title":"Lancet Planet Health"},{"issue":"7","key":"6726_CR54","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/obr.12174","volume":"15","author":"P Baker","year":"2014","unstructured":"Baker P, Friel S (2014) Processed foods and the nutrition transition: evidence from Asia. Obes Rev Off J Int Assoc Study Obes 15(7):564\u2013577. https:\/\/doi.org\/10.1111\/obr.12174","journal-title":"Obes Rev Off J Int Assoc Study Obes"},{"issue":"9","key":"6726_CR55","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1017\/s1368980012004569","volume":"16","author":"NI Lipoeto","year":"2013","unstructured":"Lipoeto NI, Geok Lin K, Angeles-Agdeppa I (2013) Food consumption patterns and nutrition transition in South-East Asia. Public Health Nutr 16(9):1637\u20131643. https:\/\/doi.org\/10.1017\/s1368980012004569","journal-title":"Public Health Nutr"},{"issue":"2","key":"6726_CR56","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4162\/nrp.2019.13.2.159","volume":"13","author":"YY Lee","year":"2019","unstructured":"Lee YY, Wan Muda WAM (2019) Dietary intakes and obesity of Malaysian adults. Nutr Res Pract 13(2):159\u2013168. https:\/\/doi.org\/10.4162\/nrp.2019.13.2.159","journal-title":"Nutr Res Pract"},{"issue":"4","key":"6726_CR57","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3803\/EnM.2020.772","volume":"35","author":"R Williams","year":"2020","unstructured":"Williams R, Periasamy M (2020) Genetic and environmental factors contributing to visceral adiposity in Asian populations. Endocrinol Metab (Seoul, Korea) 35(4):681\u2013695. https:\/\/doi.org\/10.3803\/EnM.2020.772","journal-title":"Endocrinol Metab (Seoul, Korea)"},{"issue":"16","key":"6726_CR58","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.3390\/nu14163340","volume":"14","author":"Y Liu","year":"2022","unstructured":"Liu Y, Cheng J, Wan L, Chen W (2022) Total and added sugar intakes are increasing among children and adolescents in China: findings from CHNS 1997\u20132011. Nutrients 14(16):3340. https:\/\/doi.org\/10.3390\/nu14163340","journal-title":"Nutrients"},{"issue":"10","key":"6726_CR59","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41575-024-00959-4","volume":"21","author":"S Zelber-Sagi","year":"2024","unstructured":"Zelber-Sagi S, Carrieri P, Peric\u00e0s JM, Ivancovsky-Wajcman D, Younossi ZM, Lazarus JV (2024) Food inequity and insecurity and MASLD: burden, challenges, and interventions. Nat Rev Gastroenterol Hepatol 21(10):668\u2013686. https:\/\/doi.org\/10.1038\/s41575-024-00959-4","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"6726_CR60","doi-asserted-by":"publisher","first-page":"e1715","DOI":"10.1016\/s2214-109x(22)00429-6","volume":"10","author":"A Haakenstad","year":"2022","unstructured":"Haakenstad A, Yearwood JA, Fullman N, Bintz C, Bienhoff K, Weaver MR et al (2022) Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990\u20132019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Glob Health 10(12):e1715\u2013e1743. https:\/\/doi.org\/10.1016\/s2214-109x(22)00429-6","journal-title":"Lancet Glob Health"},{"key":"6726_CR61","unstructured":"WHO (2025) World report on social determinants of health equity. WHO, Geneva. Available from: https:\/\/www.who.int\/teams\/social-determinants-of-health\/equity-and-health\/world-report-on-social-determinants-of-health-equity. Accessed: 14 Jan 2026"},{"issue":"7","key":"6726_CR62","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/ueg2.12445","volume":"11","author":"S Driessen","year":"2023","unstructured":"Driessen S, de Jong VD, van Son KC et al (2023) A global survey of health care workers\u2019 awareness of non-alcoholic fatty liver disease: the AwareNASH survey. United European Gastroenterol J 11(7):654\u2013662. https:\/\/doi.org\/10.1002\/ueg2.12445","journal-title":"United European Gastroenterol J"},{"issue":"12","key":"6726_CR63","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1007\/s11606-019-05340-9","volume":"34","author":"ER Cleveland","year":"2019","unstructured":"Cleveland ER, Ning H, Vos MB et al (2019) Low awareness of nonalcoholic fatty liver disease in a population-based cohort sample: the CARDIA study. J Gen Intern Med 34(12):2772\u20132778. https:\/\/doi.org\/10.1007\/s11606-019-05340-9","journal-title":"J Gen Intern Med"},{"issue":"4","key":"6726_CR64","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","volume":"76","author":"JV Lazarus","year":"2022","unstructured":"Lazarus JV, Mark HE, Villota-Rivas M et al (2022) The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge? J Hepatol 76(4):771\u2013780. https:\/\/doi.org\/10.1016\/j.jhep.2021.10.025","journal-title":"J Hepatol"},{"key":"6726_CR65","doi-asserted-by":"publisher","unstructured":"Lazarus JV. Pessoa MG, Shawcross DL, Schwarz P, Su GL, Barquera S (2026) Name MASLD\/MASH \u2014 and act on it. Ann Hepatol 102171. https:\/\/doi.org\/10.1016\/j.aohep.2025.102171","DOI":"10.1016\/j.aohep.2025.102171"},{"key":"6726_CR66","unstructured":"United Nations (2025) The Sustainable Development Goals Report. Available from: https:\/\/unstats.un.org\/sdgs\/report\/2025\/. Accessed: 14 Jan 2026"},{"issue":"6","key":"6726_CR67","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD et al (2024) A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"key":"6726_CR68","doi-asserted-by":"crossref","unstructured":"Stefan N, Targher G (2026) Pharmacological treatment of MASH. Diabetologia (in press)","DOI":"10.1007\/s00125-026-06796-1"},{"key":"6726_CR69","doi-asserted-by":"publisher","unstructured":"Pekarska K, Brennan PN, Ivancovsky Wajcman D et al (2025) Nutrition in MASLD: a patient focused, evidence-based clinician\u2019s guide. Frontline Gastroenterol: flgastro-2025-103183. https:\/\/doi.org\/10.1136\/flgastro-2025-103183","DOI":"10.1136\/flgastro-2025-103183"},{"issue":"12","key":"6726_CR70","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1038\/s41591-024-02958-z","volume":"30","author":"JV Lazarus","year":"2024","unstructured":"Lazarus JV, Ivancovsky Wajcman D, Mark HE et al (2024) Opportunities and challenges following approval of resmetirom for MASH liver disease. Nat Med 30(12):3402\u20133405. https:\/\/doi.org\/10.1038\/s41591-024-02958-z","journal-title":"Nat Med"},{"issue":"1","key":"6726_CR71","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1186\/s12889-022-13808-3","volume":"22","author":"E Reeve","year":"2022","unstructured":"Reeve E, Lamichhane P, McKenzie B et al (2022) The tide of dietary risks for noncommunicable diseases in Pacific Islands: an analysis of population NCD surveys. BMC Public Health 22(1):1521. https:\/\/doi.org\/10.1186\/s12889-022-13808-3","journal-title":"BMC Public Health"},{"key":"6726_CR72","doi-asserted-by":"publisher","first-page":"612531","DOI":"10.3389\/fpubh.2020.612531","volume":"8","author":"L McIver","year":"2020","unstructured":"McIver L, Manahan D, Jones S, Ulufonua L (2020) Rocketship and the rural health workforce revolution in the pacific: growing skilled medical generalists across the \u201cBlue Continent.\u201d Front Public Health 8:612531. https:\/\/doi.org\/10.3389\/fpubh.2020.612531","journal-title":"Front Public Health"},{"key":"6726_CR73","doi-asserted-by":"publisher","first-page":"100830","DOI":"10.1016\/j.lanwpc.2023.100830","volume":"39","author":"RX Qin","year":"2023","unstructured":"Qin RX, Zhang G, Lim MX et al (2023) Assessment of essential surgical and anaesthesia care capacity: a cross-sectional study in five Pacific Island Countries. Lancet Reg Health West Pac 39:100830. https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100830","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"6726_CR74","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1017\/s1368980019002118","volume":"23","author":"R Dodd","year":"2020","unstructured":"Dodd R, Reeve E, Sparks E et al (2020) The politics of food in the Pacific: coherence and tension in regional policies on nutrition, the food environment and non-communicable diseases. Public Health Nutr 23(1):168\u2013180. https:\/\/doi.org\/10.1017\/s1368980019002118","journal-title":"Public Health Nutr"},{"issue":"2","key":"6726_CR75","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/hep.0000000000000545","volume":"79","author":"JV Lazarus","year":"2024","unstructured":"Lazarus JV, Mark HE, Allen AM et al (2024) A global action agenda for turning the tide on fatty liver disease. Hepatology 79(2):502\u2013523. https:\/\/doi.org\/10.1097\/hep.0000000000000545","journal-title":"Hepatology"},{"issue":"4","key":"6726_CR76","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","volume":"67","author":"JG Fan","year":"2017","unstructured":"Fan JG, Kim SU, Wong VW (2017) New trends on obesity and NAFLD in Asia. J Hepatol 67(4):862\u2013873. https:\/\/doi.org\/10.1016\/j.jhep.2017.06.003","journal-title":"J Hepatol"},{"key":"6726_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.09.013","author":"E Vilar-Gomez","year":"2025","unstructured":"Vilar-Gomez E, Yates KP, Kleiner DE et al (2025) Genetic and non-genetic drivers of histological progression and regression in MASLD. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2025.09.013","journal-title":"J Hepatol"},{"issue":"1","key":"6726_CR78","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3350\/cmh.2024.0631","volume":"31","author":"P Danpanichkul","year":"2025","unstructured":"Danpanichkul P, Suparan K, Prasitsumrit V, Ahmed A, Wijarnpreecha K, Kim D (2025) Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations. Clin Mol Hepatol 31(1):74\u201389. https:\/\/doi.org\/10.3350\/cmh.2024.0631","journal-title":"Clin Mol Hepatol"},{"key":"6726_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-336127","author":"Z Huo","year":"2025","unstructured":"Huo Z, Chen Y, Huang Y et al (2025) Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts. Gut. https:\/\/doi.org\/10.1136\/gutjnl-2025-336127","journal-title":"Gut"},{"key":"6726_CR80","doi-asserted-by":"publisher","unstructured":"Wei JL, Leung JC, Loong TC et al (2015) Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol 110(9):1306\u20131314; quiz 1315. https:\/\/doi.org\/10.1038\/ajg.2015.235","DOI":"10.1038\/ajg.2015.235"},{"issue":"4","key":"6726_CR81","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/hep.30702","volume":"70","author":"F Zhou","year":"2019","unstructured":"Zhou F, Zhou J, Wang W et al (2019) Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatology 70(4):1119\u20131133. https:\/\/doi.org\/10.1002\/hep.30702","journal-title":"Hepatology"},{"issue":"2","key":"6726_CR82","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12072-020-10023-3","volume":"14","author":"Y Wu","year":"2020","unstructured":"Wu Y, Zheng Q, Zou B et al (2020) The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis. Hepatol Int 14(2):259\u2013269. https:\/\/doi.org\/10.1007\/s12072-020-10023-3","journal-title":"Hepatol Int"},{"key":"6726_CR83","doi-asserted-by":"publisher","unstructured":"Bilson J, Yaghootkar H (2026) Genetics of MASLD: a diabetes perpective. Diabetologia. https:\/\/doi.org\/10.1007\/s00125-026-06759-6","DOI":"10.1007\/s00125-026-06759-6"},{"issue":"5","key":"6726_CR84","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/hep.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS et al (2023) AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77(5):1797\u20131835. https:\/\/doi.org\/10.1097\/hep.0000000000000323","journal-title":"Hepatology"},{"issue":"3","key":"6726_CR85","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL), European ASsociation for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European ASsociation for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) (2024) EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81(3):492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"6726_CR86","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0094","author":"K Cusi","year":"2025","unstructured":"Cusi K, Abdelmalek MF, Apovian CM et al (2025) Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in people with diabetes: the need for screening and early intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. https:\/\/doi.org\/10.2337\/dci24-0094","journal-title":"Diabetes Care"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06726-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06726-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06726-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:39:28Z","timestamp":1790771968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-026-06726-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":86,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["6726"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06726-1","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JVL acknowledges institutional support to ISGlobal from grant CEX2023-0001290-S, funded by MCIN\/AEI\/10.13039\/501100011033, and the Generalitat de Catalunya, through the CERCA Programme. CDB is supported in part by the National Institute for Health and Care Research Southampton Biomedical Research Centre (NIHR203319).","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"JVL acknowledges grants to his institutions from Boehringer Ingelheim, Echosens, Gilead Sciences, Madrigal Pharmaceuticals, Moderna, MSD, Novo Nordisk, Pfizer and Roche Diagnostics; consulting fees from Echosens, GSK, Madrigal Pharmaceuticals, Novo Nordisk, Pfizer and Takeda; a paid leadership role at the Global NASH\/MASH Council (ended); and honoraria for lectures from AbbVie, Echosens, Gilead Sciences, GSK, Janssen, MSD, Novo Nordisk, Pfizer and Prosciento, outside this work. CDB has received research funding from Echosens outside this work. CWS has received honoraria from Novo Nordisk and Sanofi for lectures on MASLD. M-HZ\u00a0serves as a speaker for AstraZeneca, Hisky Medical Technologies and Novo Nordisk and as a consultant for Boehringer Ingelheim and Eieling Technology and has received consulting fees from Boehringer Ingelheim. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.","order":2,"name":"Ethics","label":"Authors\u2019 relationships and activities","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors were responsible for drafting different sections of the article and for reviewing the whole article critically for important intellectual content. All authors approved the final version to be published.","order":3,"name":"Ethics","label":"Contribution statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}